The usual suspects in sudden cardiac death of the young: a focus on inherited arrhythmogenic diseases

References

• Kong MH, Fonarow GC, Peterson ED, et al. Systematic review of the incidence of sudden cardiac death in the United States. J Am Coll Cardiol 2011;57(7):794-801
   PubMed Web of Science ®Google Scholar
• Lubinski A, Bissinger A, Boersma L, et al. Determinants of geographic variations in implantation of cardiac defibrillators in the European Society of Cardiology member countries--data from the European Heart Rhythm Association White Book. Europace 2011;13(5):654-62
   PubMedGoogle Scholar
• Escobedo LG, Zack MM. Comparison of sudden and nonsudden coronary deaths in the United States. Circulation 1996;93(11):2033-6
   PubMedGoogle Scholar
• Cobb LA, Fahrenbruch CE, Olsufka M, Copass MK. Changing incidence of out-of-hospital ventricular fibrillation, 1980-2000. JAMA 2002;288(23):3008-13
   PubMed Web of Science ®Google Scholar
• Zheng ZJ, Croft JB, Giles WH, Mensah GA. Sudden cardiac death in the United States, 1989 to 1998. Circulation 2001;104(18):2158-63
   PubMed Web of Science ®Google Scholar
• Eckart RE, Shry EA, Burke AP, et al. Sudden death in young adults: an autopsy-based series of a population undergoing active surveillance. J Am Coll Cardiol 2011;58(12):1254-61
   PubMed Web of Science ®Google Scholar
• Cross BJ, Estes NA III, Link MS. Sudden cardiac death in young athletes and nonathletes. Curr Opin Crit Care 2011;17(4):328-34
   PubMedGoogle Scholar
• United States Census Bureau. 2010 Census Summary File 1. Available from: www.census.gov/2010census/news/press-kits/summary-file-1.html [Last accessed 1 June 2013]
   Google Scholar
• Eurostat: population Satistics. 2010. Available from: www.europa.eu.intcomm/eurostat [Last accessed 1 June 2013]
   Google Scholar
• Maron BJ, Doerer JJ, Haas TS, et al. Sudden deaths in young competitive athletes: analysis of 1866 deaths in the United States, 1980-2006. Circulation 2009;119(8):1085-92
   PubMed Web of Science ®Google Scholar
• Corrado D, Basso C, Rizzoli G, et al. Does sports activity enhance the risk of sudden death in adolescents and young adults? J Am Coll Cardiol 2003;42(11):1959-63
   PubMed Web of Science ®Google Scholar
• Van Camp SP, Bloor CM, Mueller FO, et al. Nontraumatic sports death in high school and college athletes. Med Sci Sport Exer 1995;27(5):641-7
   PubMed Web of Science ®Google Scholar
• Holst AG, Winkel BG, Theilade J, et al. Incidence and etiology of sports-related sudden cardiac death in Denmark--implications for preparticipation screening. Heart Rhythm 2010;7(10):1365-71
   PubMed Web of Science ®Google Scholar
• Topaz O, Edwards JE. Pathologic features of sudden death in children, adolescents, and young adults. Chest 1985;87(4):476-82
   PubMedGoogle Scholar
• Drory Y, Turetz Y, Hiss Y, et al. Sudden unexpected death in persons less than 40 years of age. Am J Cardiol 1991;68(13):1388-92
   PubMedGoogle Scholar
• Shen WK, Edwards WD, Hammill SC, et al. Sudden unexpected nontraumatic death in 54 young adults: a 30-year population-based study. Am J Cardiol 1995;76(3):148-52
   PubMed Web of Science ®Google Scholar
• Wisten A, Forsberg H, Krantz P, Messner T. Sudden cardiac death in 15-35-year olds in Sweden during 1992-99. J Intern Med 2002;252(6):529-36
   PubMedGoogle Scholar
• Cho Y, Park T, Yang DH, et al. Arrhythmogenic right ventricular cardiomyopathy and sudden cardiac death in young Koreans. Circ J 2003;67(11):925-8
   PubMedGoogle Scholar
• Eckart RE, Scoville SL, Campbell CL, et al. Sudden death in young adults: a 25-year review of autopsies in military recruits. Ann Intern Med 2004;141(11):829-34
   PubMed Web of Science ®Google Scholar
• Puranik R, Chow CK, Duflou JA, et al. Sudden death in the young. Heart Rhythm 2005;2(12):1277-82
   PubMed Web of Science ®Google Scholar
• di Gioia CR, Autore C, Romeo DM, et al. Sudden cardiac death in younger adults: autopsy diagnosis as a tool for preventive medicine. Hum Pathol 2006;37(7):794-801
   PubMedGoogle Scholar
• Papadakis M, Sharma S, Cox S, et al. The magnitude of sudden cardiac death in the young: a death certificate-based review in England and Wales. Europace 2009;11(10):1353-8
   PubMedGoogle Scholar
• Lim Z, Gibbs K, Potts JE, Sanatani S. A review of sudden unexpected death in the young in British Columbia. Can J Cardiol 2010;26(1):22-6
   PubMedGoogle Scholar
• Fragkouli K, Vougiouklakis T. Sudden cardiac death: an 11-year postmortem analysis in the region of Epirus, Greece. Pathol Res Pract 2010;206(10):690-4
   PubMedGoogle Scholar
• Winkel BG, Holst AG, Theilade J, et al. Nationwide study of sudden cardiac death in persons aged 1-35 years. Eur Heart J 2011;32(8):983-90
   PubMedGoogle Scholar
• Margey R, Roy A, Tobin S, et al. Sudden cardiac death in 14- to 35-year olds in Ireland from 2005 to 2007: a retrospective registry. Europace 2011;13(10):1411-18
   PubMedGoogle Scholar
• Pilmer CM, Porter B, Kirsh JA, et al. Scope and nature of sudden cardiac death before age 40 in Ontario: a report from the cardiac death advisory committee of the office of the chief coroner. Heart Rhythm 2013;10(4):517-23
   PubMedGoogle Scholar
• Winkel BG, Larsen MK, Berge KE, et al. The prevalence of mutations in KCNQ1, KCNH2, and SCN5A in an unselected national cohort of young sudden unexplained death cases. J Cardiovasc Electrophysiol 2012;23(10):1092-8
   PubMedGoogle Scholar
• Mazzanti A, Priori SG. Molecular autopsy for sudden unexplained death? Time to discuss pros and cons. J Cardiovasc Electrophysiol 2012;23(10):1099-102
   PubMedGoogle Scholar
• Maron BJ, Gardin JM, Flack JM, et al. Prevalence of hypertrophic cardiomyopathy in a general population of young adults. Echocardiographic analysis of 4111 subjects in the CARDIA Study. Coronary Artery Risk Development in (Young) Adults. Circulation 1995;92(4):785-9
   PubMed Web of Science ®Google Scholar
• Frances RJ. Arrhythmogenic right ventricular dysplasia/cardiomyopathy. A review and update. Int J Cardiol 2006;110(3):279-87
   PubMedGoogle Scholar
• Thiene G, Corrado D, Basso C. Arrhythmogenic right ventricular cardiomyopathy/dysplasia. Orphanet J Rare Dis 2007;2:45
   PubMed Web of Science ®Google Scholar
• Codd MB, Sugrue DD, Gersh BJ, Melton LJ III. Epidemiology of idiopathic dilated and hypertrophic cardiomyopathy. A population-based study in Olmsted County, Minnesota, 1975-1984. Circulation 1989;80(3):564-72
   PubMed Web of Science ®Google Scholar
• Schwartz PJ, Stramba-Badiale M, Crotti L, et al. Prevalence of the congenital long-QT syndrome. Circulation 2009;120(18):1761-7
   PubMed Web of Science ®Google Scholar
• Fowler SJ, Priori SG. Clinical spectrum of patients with a Brugada ECG. Curr Opin Cardiol 2009;24(1):74-81
   PubMedGoogle Scholar
• Napolitano C, Priori SG, Bloise R. Catecholaminergic polymorphic ventricular tachycardia. In: Pagon RA, Bird TD, Dolan CR, Stephens K, Adam MP, editors. Gene reviews. Seattle; WA, USA: 1993
   Google Scholar
• Giustetto C, Schimpf R, Mazzanti A, et al. Long-term follow-up of patients with short QT syndrome. J Am Coll Cardiol 2011;58(6):587-95
   PubMed Web of Science ®Google Scholar
• Prevalence of rare diseases: bibliographic data, Orphanet Report Series, Rare Diseases collection, June 2013, Number 1 : Listed in alphabetical order of disease or group of diseases. Available from: www.orpha.net/orphacom/cahiers/docs/GB/Prevalence_of_rare_diseases_by_alphabetical_list.pdf
   Google Scholar
• Priori SG, Schwartz PJ, Napolitano C, et al. Risk stratification in the long-QT syndrome. N Engl J Med 2003;348(19):1866-74
   PubMed Web of Science ®Google Scholar
• Geisterfer-Lowrance AA, Kass S, Tanigawa G, et al. A molecular basis for familial hypertrophic cardiomyopathy: a beta cardiac myosin heavy chain gene missense mutation. Cell 1990;62(5):999-1006
   PubMedGoogle Scholar
• Curran ME, Splawski I, Timothy KW, et al. A molecular basis for cardiac arrhythmia: HERG mutations cause long QT syndrome. Cell 1995;80(5):795-803
   PubMed Web of Science ®Google Scholar
• Ackerman MJ, Priori SG, Willems S, et al. HRS/EHRA expert consensus statement on the state of genetic testing for the channelopathies and cardiomyopathies this document was developed as a partnership between the Heart Rhythm Society (HRS) and the European Heart Rhythm Association (EHRA). Heart Rhythm 2011;8(8):1308-39
   PubMed Web of Science ®Google Scholar
• Mitani Y, Ohta K, Yodoya N, et al. Public access defibrillation improved the outcome after out-of-hospital cardiac arrest in school-age children: a nationwide, population-based, Utstein registry study in Japan. Europace 2013;15(9):1259-66
   PubMedGoogle Scholar
• Priori SG, Wilde AA, Horie M, et al. HRS/EHRA/APHRS Expert consensus statement on the diagnosis and management of patients with inherited primary arrhythmia syndromesexpert consensus statement on inherited primary arrhythmia syndromes: document endorsed by HRS, EHRA, and APHRS in May 2013 and by ACCF, AHA, PACES, and AEPC in June 2013. Heart Rhythm 2013;e75-e106
   Google Scholar
• Earle N, Crawford J, Smith W, et al. Community detection of long QT syndrome with a clinical registry: an alternative to ECG screening programs? Heart Rhythm 2013;10(2):233-8
   PubMed Web of Science ®Google Scholar
• Priori SG, Napolitano C, Gasparini M, et al. Natural history of Brugada syndrome: insights for risk stratification and management. Circulation 2002;105(11):1342-7
   PubMed Web of Science ®Google Scholar
• Priori SG, Napolitano C, Memmi M, et al. Clinical and molecular characterization of patients with catecholaminergic polymorphic ventricular tachycardia. Circulation 2002;106(1):69-74
   PubMed Web of Science ®Google Scholar
• Priori SG, Gasparini M, Napolitano C, et al. Risk stratification in Brugada syndrome: results of the PRELUDE (PRogrammed ELectrical stimUlation preDictive valuE) registry. J Am Coll Cardiol 2012;59(1):37-45
   PubMed Web of Science ®Google Scholar
• Mazzanti A, Kanthan A, Monteforte N. Novel insights in the natural history of short QT syndrome. J Am Coll Cardiol 2013. [Epub ahead of print]
   PubMedGoogle Scholar
• Bai R, Napolitano C, Bloise R, et al. Yield of genetic screening in inherited cardiac channelopathies: how to prioritize access to genetic testing. Circ Arrhythm Electrophysiol 2009;2(1):6-15
   PubMed Web of Science ®Google Scholar
• Elliott P, Andersson B, Arbustini E, et al. Classification of the cardiomyopathies: a position statement from the European Society Of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J 2008;29(2):270-6
   PubMed Web of Science ®Google Scholar
• Maron BJ. Sudden death in young athletes. N Engl J Med 2003;349(11):1064-75
   PubMed Web of Science ®Google Scholar
• Gersh BJ, Maron BJ, Bonow RO, et al. 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Thorac Cardiov Surg 2011;142(6):1303-38
   PubMed Web of Science ®Google Scholar
• Marcus FI, McKenna WJ, Sherrill D, et al. Diagnosis of arrhythmogenic right ventricular cardiomyopathy/dysplasia: proposed modification of the Task Force Criteria. Eur Heart J 2010;31(7):806-14
   PubMed Web of Science ®Google Scholar
• Dickstein K, Cohen-Solal A, Filippatos G, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the task force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur J Heart Fail 2008;10(10):933-89
   PubMed Web of Science ®Google Scholar
• Epstein AE, DiMarco JP, Ellenbogen KA, et al. ACC/AHA/HRS 2008 Guidelines for device-based therapy of cardiac rhythm abnormalities: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline update for implantation of cardiac pacemakers and antiarrhythmia devices) developed in collaboration with the American Association for Thoracic Surgery and Society of Thoracic Surgeons. J Am Coll Cardiol 2008;51(21):e1-62
   PubMed Web of Science ®Google Scholar
• Epstein AE, DiMarco JP, Ellenbogen KA, et al. 2012 ACCF/AHA/HRS focused update incorporated into the ACCF/AHA/HRS 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. Circulation 2013;127(3):e283-352
   PubMed Web of Science ®Google Scholar
• McMurray JJ, Adamopoulos S, Anker SD, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The task force for the diagnosis and treatment of acute and chronic heart failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J 2012;33(14):1787-847
   PubMed Web of Science ®Google Scholar
• al-Mahdawi S, Chamberlain S, Chojnowska L, et al. The electrocardiogram is a more sensitive indicator than echocardiography of hypertrophic cardiomyopathy in families with a mutation in the MYH7 gene. Br Heart J 1994;72(2):105-11
   PubMedGoogle Scholar
• Pelliccia A, Di Paolo FM, Quattrini FM, et al. Outcomes in athletes with marked ECG repolarization abnormalities. N Engl J Med 2008;358(2):152-61
   PubMedGoogle Scholar
• Gomes J, Finlay M, Ahmed AK, et al. Electrophysiological abnormalities precede overt structural changes in arrhythmogenic right ventricular cardiomyopathy due to mutations in desmoplakin-A combined murine and human study. Eur Heart J 2012;33(15):1942-53
   PubMed Web of Science ®Google Scholar
• Gimeno JR, Lacunza J, Garcia-Alberola A, et al. Penetrance and risk profile in inherited cardiac diseases studied in a dedicated screening clinic. Am J Cardiol 2009;104(3):406-10
   PubMedGoogle Scholar
• Michels M, Soliman OI, Phefferkorn J, et al. Disease penetrance and risk stratification for sudden cardiac death in asymptomatic hypertrophic cardiomyopathy mutation carriers. Eur Heart J 2009;30(21):2593-8
   PubMedGoogle Scholar
• Mestroni L, Rocco C, Gregori D, et al. Familial dilated cardiomyopathy: evidence for genetic and phenotypic heterogeneity. Heart Muscle Disease Study Group. J Am Coll Cardiol 1999;34(1):181-90
   PubMedGoogle Scholar
• Quarta G, Muir A, Pantazis A, et al. Familial evaluation in arrhythmogenic right ventricular cardiomyopathy: impact of genetics and revised task force criteria. Circulation 2011;123(23):2701-9
   PubMed Web of Science ®Google Scholar
• Elliott P, McKenna WJ. Hypertrophic cardiomyopathy. Lancet 2004;363(9424):1881-91
   PubMed Web of Science ®Google Scholar
• Katz A. Physiology of the heart. Lippincott Williams & Wilkins, PA, USA; 2010
   Google Scholar
• Moak JP, Kaski JP. Hypertrophic cardiomyopathy in children. Heart 2012;98(14):1044-54
   PubMedGoogle Scholar
• Jacoby D, McKenna WJ. Genetics of inherited cardiomyopathy. Eur Heart J 2012;33(3):296-304
   PubMedGoogle Scholar
• Wigle ED, Sasson Z, Henderson MA, et al. Hypertrophic cardiomyopathy. The importance of the site and the extent of hypertrophy. A review. Prog Cardiovasc Dis 1985;28(1):1-83
   PubMed Web of Science ®Google Scholar
• Critoph C, Elliot P. Hypertrophic cardiomyopathy. Cardiac Electrophysiol Clin 2010;2(4):587-98
   PubMedGoogle Scholar
• Varnava AM, Elliott PM, Sharma S, et al. Hypertrophic cardiomyopathy: the interrelation of disarray, fibrosis, and small vessel disease. Heart 2000;84(5):476-82
   PubMed Web of Science ®Google Scholar
• Elliott PM, Gimeno JR, Thaman R, et al. Historical trends in reported survival rates in patients with hypertrophic cardiomyopathy. Heart 2006;92(6):785-91
   PubMed Web of Science ®Google Scholar
• Spirito P, Maron BJ, Bonow RO, Epstein SE. Occurrence and significance of progressive left ventricular wall thinning and relative cavity dilatation in hypertrophic cardiomyopathy. Am J Cardiol 1987;60(1):123-9
   PubMedGoogle Scholar
• Zipes DP, Camm AJ, Borggrefe M, et al. ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death). J Am Coll Cardiol 2006;48(5):e247-346
   PubMed Web of Science ®Google Scholar
• Watkins H, Rosenzweig A, Hwang DS, et al. Characteristics and prognostic implications of myosin missense mutations in familial hypertrophic cardiomyopathy. N Engl J Med 1992;326(17):1108-14
   PubMed Web of Science ®Google Scholar
• Maron BJ, McKenna WJ, Danielson GK, et al. American College of Cardiology/European Society of Cardiology Clinical Expert Consensus Document on Hypertrophic Cardiomyopathy. A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines. Eur Heart J 2003;24(21):1965-91
   PubMedGoogle Scholar
• McKenna WJ, Oakley CM, Krikler DM, Goodwin JF. Improved survival with amiodarone in patients with hypertrophic cardiomyopathy and ventricular tachycardia. Br Heart J 1985;53(4):412-16
   PubMedGoogle Scholar
• Marcus FI, Fontaine GH, Guiraudon G, et al. Right ventricular dysplasia: a report of 24 adult cases. Circulation 1982;65(2):384-98
   PubMed Web of Science ®Google Scholar
• Sen-Chowdhry S, Morgan RD, Chambers JC, McKenna WJ. Arrhythmogenic cardiomyopathy: etiology, diagnosis, and treatment. Ann Rev Med 2010;61:233-53
   PubMed Web of Science ®Google Scholar
• Norman M, Simpson M, Mogensen J, et al. Novel mutation in desmoplakin causes arrhythmogenic left ventricular cardiomyopathy. Circulation 2005;112(5):636-42
   PubMedGoogle Scholar
• Elliott P, O’Mahony C, Syrris P, et al. Prevalence of desmosomal protein gene mutations in patients with dilated cardiomyopathy. Circ Cardiovasc Genet 2010;3(4):314-22
   PubMedGoogle Scholar
• Tabib A, Loire R, Chalabreysse L, et al. Circumstances of death and gross and microscopic observations in a series of 200 cases of sudden death associated with arrhythmogenic right ventricular cardiomyopathy and/or dysplasia. Circulation 2003;108(24):3000-5
   PubMed Web of Science ®Google Scholar
• Sen-Chowdhry S, Syrris P, Ward D, et al. Clinical and genetic characterization of families with arrhythmogenic right ventricular dysplasia/cardiomyopathy provides novel insights into patterns of disease expression. Circulation 2007;115(13):1710-20
   PubMed Web of Science ®Google Scholar
• Saffitz JE. The pathobiology of arrhythmogenic cardiomyopathy. Ann Rev Pathol 2011;6:299-321
   PubMed Web of Science ®Google Scholar
• Coonar AS, Protonotarios N, Tsatsopoulou A, et al. Gene for arrhythmogenic right ventricular cardiomyopathy with diffuse nonepidermolytic palmoplantar keratoderma and woolly hair (Naxos disease) maps to 17q21. Circulation 1998;97(20):2049-58
   PubMed Web of Science ®Google Scholar
• McKoy G, Protonotarios N, Crosby A, et al. Identification of a deletion in plakoglobin in arrhythmogenic right ventricular cardiomyopathy with palmoplantar keratoderma and woolly hair (Naxos disease). Lancet 2000;355(9221):2119-24
   PubMed Web of Science ®Google Scholar
• Norgett EE, Hatsell SJ, Carvajal-Huerta L, et al. Recessive mutation in desmoplakin disrupts desmoplakin-intermediate filament interactions and causes dilated cardiomyopathy, woolly hair and keratoderma. Hum Mol Genet 2000;9(18):2761-6
   PubMed Web of Science ®Google Scholar
• Syrris P, Ward D, Asimaki A, et al. Clinical expression of plakophilin-2 mutations in familial arrhythmogenic right ventricular cardiomyopathy. Circulation 2006;113(3):356-64
   PubMedGoogle Scholar
• Xu T, Yang Z, Vatta M, et al. Compound and digenic heterozygosity contributes to arrhythmogenic right ventricular cardiomyopathy. J Am Coll Cardiol 2010;55(6):587-97
   PubMed Web of Science ®Google Scholar
• Rigato I, Bauce B, Rampazzo A, et al. Compound and digenic heterozygosity predicts life-time arrhythmic outcome and sudden cardiac death in desmosomal gene-related arrhythmogenic right ventricular cardiomyopathy. Circ Cardiovasc Genet 2013;6(6):533-42
   PubMedGoogle Scholar
• Dalal D, Nasir K, Bomma C, et al. Arrhythmogenic right ventricular dysplasia: a United States experience. Circulation 2005;112(25):3823-32
   PubMed Web of Science ®Google Scholar
• Peters S, Trummel M, Meyners W. Prevalence of right ventricular dysplasia-cardiomyopathy in a non-referral hospital. Int J Cardiol 2004;97(3):499-501
   PubMed Web of Science ®Google Scholar
• Nava A, Bauce B, Basso C, et al. Clinical profile and long-term follow-up of 37 families with arrhythmogenic right ventricular cardiomyopathy. J Am Coll Cardiol 2000;36(7):2226-33
   PubMed Web of Science ®Google Scholar
• Hamid MS, Norman M, Quraishi A, et al. Prospective evaluation of relatives for familial arrhythmogenic right ventricular cardiomyopathy/dysplasia reveals a need to broaden diagnostic criteria. J Am Coll Cardiol 2002;40(8):1445-50
   PubMedGoogle Scholar
• Kirchhof P, Fabritz L, Zwiener M, et al. Age- and training-dependent development of arrhythmogenic right ventricular cardiomyopathy in heterozygous plakoglobin-deficient mice. Circulation 2006;114(17):1799-806
   PubMed Web of Science ®Google Scholar
• James CA, Bhonsale A, Tichnell C, et al. Exercise increases age-related penetrance and arrhythmic risk in arrhythmogenic right ventricular dysplasia/cardiomyopathy-associated desmosomal mutation carriers. J Am Coll Cardiol 2013;62(14):1290-7
   PubMed Web of Science ®Google Scholar
• Corrado D, Basso C, Pilichou K, Thiene G. Molecular biology and clinical management of arrhythmogenic right ventricular cardiomyopathy/dysplasia. Heart 2011;97(7):530-9
   PubMed Web of Science ®Google Scholar
• Paul M, Wichter T, Fabritz L, et al. Arrhythmogenic right ventricular cardiomyopathy: an update on pathophysiology, genetics, diagnosis, and risk stratification. Herzschrittmacherther Elektrophysiol 2012;23(3):186-95
   PubMedGoogle Scholar
• Calkins H. Arrhythmogenic right-ventricular dysplasia/cardiomyopathy. Curr Opin Cardiol 2006;21(1):55-63
   PubMedGoogle Scholar
• Wichter T, Borggrefe M, Haverkamp W, et al. Efficacy of antiarrhythmic drugs in patients with arrhythmogenic right ventricular disease. Results in patients with inducible and noninducible ventricular tachycardia. Circulation 1992;86(1):29-37
   PubMed Web of Science ®Google Scholar
• Marcus GM, Glidden DV, Polonsky B, et al. Efficacy of antiarrhythmic drugs in arrhythmogenic right ventricular cardiomyopathy: a report from the North American ARVC Registry. J Am Coll Cardiol 2009;54(7):609-15
   PubMed Web of Science ®Google Scholar
• Mestroni L, Maisch B, McKenna WJ, et al. Guidelines for the study of familial dilated cardiomyopathies. Collaborative Research Group of the European Human and Capital Mobility Project on Familial Dilated Cardiomyopathy. Eur Heart J 1999;20(2):93-102
   PubMedGoogle Scholar
• Baig MK, Goldman JH, Caforio AL, et al. Familial dilated cardiomyopathy: cardiac abnormalities are common in asymptomatic relatives and may represent early disease. J Am Coll Cardiol 1998;31(1):195-201
   PubMedGoogle Scholar
• Hershberger RE, Parks SB, Kushner JD, et al. Coding sequence mutations identified in MYH7, TNNT2, SCN5A, CSRP3, LBD3, and TCAP from 313 patients with familial or idiopathic dilated cardiomyopathy. Clin Transl Sci 2008;1(1):21-6
   PubMedGoogle Scholar
• Arbustini E, Pilotto A, Repetto A, et al. Autosomal dominant dilated cardiomyopathy with atrioventricular block: a lamin A/C defect-related disease. J Am Coll Cardiol 2002;39(6):981-90
   PubMed Web of Science ®Google Scholar
• van Rijsingen IA, Arbustini E, Elliott PM, et al. Risk factors for malignant ventricular arrhythmias in lamin a/c mutation carriers a European cohort study. J Am Coll Cardiol 2012;59(5):493-500
   PubMed Web of Science ®Google Scholar
• Mahon NG, Murphy RT, MacRae CA, et al. Echocardiographic evaluation in asymptomatic relatives of patients with dilated cardiomyopathy reveals preclinical disease. Ann Intern Med 2005;143(2):108-15
   PubMed Web of Science ®Google Scholar
• Kamisago M, Sharma SD, DePalma SR, et al. Mutations in sarcomere protein genes as a cause of dilated cardiomyopathy. N Engl J Med 2000;343(23):1688-96
   PubMed Web of Science ®Google Scholar
• Dec GW, Fuster V. Idiopathic dilated cardiomyopathy. N Engl J Med 1994;331(23):1564-75
   PubMedGoogle Scholar
• Di Lenarda A, Secoli G, Perkan A, et al. Changing mortality in dilated cardiomyopathy. The Heart Muscle Disease Study Group. Br Heart J 1994;72(6 Suppl):S46-51
   Google Scholar
• CIBIS-II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 1999;353(9146):9-13
   PubMed Web of Science ®Google Scholar
• Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999;341(10):709-17
   PubMed Web of Science ®Google Scholar
• Zecchin M, Di Lenarda A, Gregori D, et al. Are nonsustained ventricular tachycardias predictive of major arrhythmias in patients with dilated cardiomyopathy on optimal medical treatment? Pacing Clin Electrophysiol 2008;31(3):290-9
   PubMedGoogle Scholar
• Disertori M, Quintarelli S, Mazzola S, et al. The need to modify patient selection to improve the benefits of implantable cardioverter-defibrillator for primary prevention of sudden death in non-ischaemic dilated cardiomyopathy. Europace 2013;15(12):1693-701
   PubMedGoogle Scholar
• Maron BJ, Towbin JA, Thiene G, et al. Contemporary definitions and classification of the cardiomyopathies: an American Heart Association Scientific Statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; and Council on Epidemiology and Prevention. Circulation 2006;113(14):1807-16
   PubMed Web of Science ®Google Scholar
• Schwartz PJ, Priori SG, Napolitano C. The long QT syndrome. In: Zipes DP, Jalife J, editors. Cardiac electrophysiology form cell to bedside. WB Saunders; Philadelphia, PA, USA: 2000. p. 597-615
   Google Scholar
• Jervell A, Lange-Nielsen F. Congenital deaf-mutism, functional heart disease with prolongation of the Q-T interval and sudden death. Am Heart J 1957;54(1):59-68
   PubMed Web of Science ®Google Scholar
• Tranebjaerg L, Bathen J, Tyson J, Bitner-Glindzicz M. Jervell and Lange-Nielsen syndrome: a Norwegian perspective. Am J Med Genet 1999;89(3):137-46
   PubMedGoogle Scholar
• Wang Q, Shen J, Splawski I, et al. SCN5A mutations associated with an inherited cardiac arrhythmia, long QT syndrome. Cell 1995;80(5):805-11
   PubMed Web of Science ®Google Scholar
• Wang Q, Curran ME, Splawski I, et al. Positional cloning of a novel potassium channel gene: KVLQT1 mutations cause cardiac arrhythmias. Nat Genet 1996;12(1):17-23
   PubMed Web of Science ®Google Scholar
• Dessertenne F, Coumel P, Fabiato A. [Ventricular fibrillation and twisted peaks]. Presse Med 1969;77(6):193-6
   Google Scholar
• Schwartz PJ, Priori SG, Spazzolini C, et al. Genotype-phenotype correlation in the long-QT syndrome: gene-specific triggers for life-threatening arrhythmias. Circulation 2001;103(1):89-95
   PubMed Web of Science ®Google Scholar
• Moss AJ, Schwartz PJ, Crampton RS, et al. The long QT syndrome. Prospective longitudinal study of 328 families. Circulation 1991;84(3):1136-44
   PubMed Web of Science ®Google Scholar
• Priori SG, Napolitano C, Schwartz PJ, et al. Association of long QT syndrome loci and cardiac events among patients treated with beta-blockers. JAMA 2004;292(11):1341-4
   PubMed Web of Science ®Google Scholar
• Spazzolini C, Mullally J, Moss AJ, et al. Clinical implications for patients with long QT syndrome who experience a cardiac event during infancy. J Am Coll Cardiol 2009;54(9):832-7
   PubMedGoogle Scholar
• Schwartz PJ, Crotti L. QTc behavior during exercise and genetic testing for the long-QT syndrome. Circulation 2011;124(20):2181-4
   PubMed Web of Science ®Google Scholar
• Liu JF, Jons C, Moss AJ, et al. Risk factors for recurrent syncope and subsequent fatal or near-fatal events in children and adolescents with long QT syndrome. J Am Coll Cardiol 2011;57(8):941-50
   PubMed Web of Science ®Google Scholar
• Zhang L, Timothy KW, Vincent GM, et al. Spectrum of ST-T-wave patterns and repolarization parameters in congenital long-QT syndrome: ECG findings identify genotypes. Circulation 2000;102(23):2849-55
   PubMedGoogle Scholar
• Zareba W, Moss AJ, Schwartz PJ, et al. Influence of genotype on the clinical course of the long-QT syndrome. International Long-QT Syndrome Registry Research Group. N Engl J Med 1998;339(14):960-5
   PubMed Web of Science ®Google Scholar
• Moss AJ, Shimizu W, Wilde AA, et al. Clinical aspects of type-1 long-QT syndrome by location, coding type, and biophysical function of mutations involving the KCNQ1 gene. Circulation 2007;115(19):2481-9
   PubMed Web of Science ®Google Scholar
• Shimizu W, Moss AJ, Wilde AA, et al. Genotype-phenotype aspects of type 2 long QT syndrome. J Am Coll Cardiol 2009;54(22):2052-62
   PubMedGoogle Scholar
• Shimizu W, Horie M, Ohno S, et al. Mutation site-specific differences in arrhythmic risk and sensitivity to sympathetic stimulation in the LQT1 form of congenital long QT syndrome: multicenter study in Japan. J Am Coll Cardiol 2004;44(1):117-25
   PubMedGoogle Scholar
• Moss AJ, Zareba W, Kaufman ES, et al. Increased risk of arrhythmic events in long-QT syndrome with mutations in the pore region of the human ether-a-go-go-related gene potassium channel. Circulation 2002;105(7):794-9
   PubMed Web of Science ®Google Scholar
• Crotti L, Spazzolini C, Schwartz PJ, et al. The common long-QT syndrome mutation KCNQ1/A341V causes unusually severe clinical manifestations in patients with different ethnic backgrounds: toward a mutation-specific risk stratification. Circulation 2007;116(21):2366-75
   PubMed Web of Science ®Google Scholar
• The credible source for information on medicines. Available from: www.qtdrugs.org
   Google Scholar
• Schwartz PJ, Spazzolini C, Crotti L. All LQT3 patients need an ICD: true or false? Heart Rhythm 2009;6(1):113-20
   PubMed Web of Science ®Google Scholar
• Ruan Y, Liu N, Bloise R, et al. Gating properties of SCN5A mutations and the response to mexiletine in long-QT syndrome type 3 patients. Circulation 2007;116(10):1137-44
   PubMed Web of Science ®Google Scholar
• Schwartz PJ, Priori SG, Locati EH, et al. Long QT syndrome patients with mutations of the SCN5A and HERG genes have differential responses to Na+ channel blockade and to increases in heart rate. Implications for gene-specific therapy. Circulation 1995;92(12):3381-6
   PubMedGoogle Scholar
• Schwartz PJ, Priori SG, Cerrone M, et al. Left cardiac sympathetic denervation in the management of high-risk patients affected by the long-QT syndrome. Circulation 2004;109(15):1826-33
   PubMed Web of Science ®Google Scholar
• Gaita F, Giustetto C, Bianchi F, et al. Short QT Syndrome: a familial cause of sudden death. Circulation 2003;108(8):965-70
   PubMed Web of Science ®Google Scholar
• Antzelevitch C, Pollevick GD, Cordeiro JM, et al. Loss-of-function mutations in the cardiac calcium channel underlie a new clinical entity characterized by ST-segment elevation, short QT intervals, and sudden cardiac death. Circulation 2007;115(4):442-9
   PubMed Web of Science ®Google Scholar
• Deo M, Ruan Y, Pandit SV, et al. KCNJ2 mutation in short QT syndrome 3 results in atrial fibrillation and ventricular proarrhythmia. Proc Natl Acad Sci USA 2013;110(11):4291-6
   PubMed Web of Science ®Google Scholar
• Giustetto C SC, Giachino D, Antzelevitch C, Gaita F. Short QT syndrome. Cardiogenetics 2011;1(Suppl 1):e5
   Google Scholar
• Rautaharju PM, Surawicz B, Gettes LS, et al. AHA/ACCF/HRS recommendations for the standardization and interpretation of the electrocardiogram: part IV: the ST segment, T and U waves, and the QT interval. Circulation 2009;119(10):e241-50
   PubMed Web of Science ®Google Scholar
• Brugada P, Brugada J. Right bundle branch block, persistent ST segment elevation and sudden cardiac death: a distinct clinical and electrocardiographic syndrome. A multicenter report. J Am Coll Cardiol 1992;20(6):1391-6
   PubMed Web of Science ®Google Scholar
• Gehi AK, Duong TD, Metz LD, et al. Risk stratification of individuals with the Brugada electrocardiogram: a meta-analysis. J Cardiovasc Electrophysiol 2006;17(6):577-83
   PubMed Web of Science ®Google Scholar
• Bezzina CR, Shimizu W, Yang P, et al. Common sodium channel promoter haplotype in asian subjects underlies variability in cardiac conduction. Circulation 2006;113(3):338-44
   PubMed Web of Science ®Google Scholar
• Di Diego JM, Cordeiro JM, Goodrow RJ, et al. Ionic and cellular basis for the predominance of the Brugada syndrome phenotype in males. Circulation 2002;106(15):2004-11
   PubMed Web of Science ®Google Scholar
• Shimizu W, Matsuo K, Kokubo Y, et al. Sex hormone and gender difference--role of testosterone on male predominance in Brugada syndrome. J Cardiovasc Electrophysiol 2007;18(4):415-21
   PubMed Web of Science ®Google Scholar
• Mizusawa Y, Wilde AA. Brugada syndrome. Circ Arrhythm Electrophysiol 2012;5(3):606-16
   PubMed Web of Science ®Google Scholar
• Antzelevitch C, Brugada R. Fever and Brugada syndrome. Pacing Clin Electrophysiol 2002;25(11):1537-9
   PubMed Web of Science ®Google Scholar
• Ikeda T, Abe A, Yusu S, et al. The full stomach test as a novel diagnostic technique for identifying patients at risk of Brugada syndrome. J Cardiovasc Electrophysiol 2006;17(6):602-7
   PubMedGoogle Scholar
• Ohkubo K, Nakai T, Watanabe I. Alcohol-induced ventricular fibrillation in a case of Brugada syndrome. Europace 2013;15(7):1058
   PubMedGoogle Scholar
• Matsuo K, Kurita T, Inagaki M, et al. The circadian pattern of the development of ventricular fibrillation in patients with Brugada syndrome. Eur Heart J 1999;20(6):465-70
   PubMed Web of Science ®Google Scholar
• Safe drug use and the Brudga syndrome. Available from: www.brugadadrugs.org
   Google Scholar
• Paul M, Gerss J, Schulze-Bahr E, et al. Role of programmed ventricular stimulation in patients with Brugada syndrome: a meta-analysis of worldwide published data. Eur Heart J 2007;28(17):2126-33
   PubMedGoogle Scholar
• Morita H, Kusano KF, Miura D, et al. Fragmented QRS as a marker of conduction abnormality and a predictor of prognosis of Brugada syndrome. Circulation 2008;118(17):1697-704
   PubMed Web of Science ®Google Scholar
• Meregalli PG, Tan HL, Probst V, et al. Type of SCN5A mutation determines clinical severity and degree of conduction slowing in loss-of-function sodium channelopathies. Heart Rhythm 2009;6(3):341-8
   PubMedGoogle Scholar
• Maury P, Hocini M, Haissaguerre M. Electrical storms in Brugada syndrome: review of pharmacologic and ablative therapeutic options. Indian Pacing Electrophysiol J 2005;5(1):25-34
   PubMedGoogle Scholar
• Belhassen B, Viskin S, Fish R, et al. Effects of electrophysiologic-guided therapy with Class IA antiarrhythmic drugs on the long-term outcome of patients with idiopathic ventricular fibrillation with or without the Brugada syndrome. J Cardiovasc Electrophysiol 1999;10(10):1301-12
   PubMed Web of Science ®Google Scholar
• Belhassen B, Glick A, Viskin S. Excellent long-term reproducibility of the electrophysiologic efficacy of quinidine in patients with idiopathic ventricular fibrillation and Brugada syndrome. Pacing Clin Electrophysiol 2009;32(3):294-301
   PubMed Web of Science ®Google Scholar
• Marquez MF, Bonny A, Hernandez-Castillo E, et al. Long-term efficacy of low doses of quinidine on malignant arrhythmias in Brugada syndrome with an implantable cardioverter-defibrillator: a case series and literature review. Heart Rhythm 2012;9(12):1995-2000
   PubMed Web of Science ®Google Scholar
• Viskin S. A prospective trial of empiric quinidine therapy for asymptomatic Brugada syndrome. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2008. NLM Identifier: NCT00789165 Available from: http://clinicaltrials.gov/showNCT00789165 [Last accessed 1 June 2013]
   Google Scholar
• Viskin S, Wilde AA, Guevara-Valdivia ME, et al. Quinidine, a life-saving medication for Brugada syndrome, is inaccessible in many countries. J Am Coll Cardiol 2013;61(23):2383-7
   PubMed Web of Science ®Google Scholar
• Nademanee K, Veerakul G, Chandanamattha P, et al. Prevention of ventricular fibrillation episodes in Brugada syndrome by catheter ablation over the anterior right ventricular outflow tract epicardium. Circulation 2011;123(12):1270-9
   PubMed Web of Science ®Google Scholar
• Coumel P. Catecholamine-induced severe ventricular arrhythmias with Adams-Stokes syndrome in children: a report of four cases. Br Heart J 1978;40(suppl):28-37
   Google Scholar
• Leenhardt A, Glaser E, Burguera M, et al. Short-coupled variant of torsade de pointes. A new electrocardiographic entity in the spectrum of idiopathic ventricular tachyarrhythmias. Circulation 1994;89(1):206-15
   PubMed Web of Science ®Google Scholar
• Priori SG, Napolitano C, Tiso N, et al. Mutations in the cardiac ryanodine receptor gene (hRyR2) underlie catecholaminergic polymorphic ventricular tachycardia. Circulation 2001;103(2):196-200
   PubMed Web of Science ®Google Scholar
• Lahat H, Pras E, Olender T, et al. A missense mutation in a highly conserved region of CASQ2 is associated with autosomal recessive catecholamine-induced polymorphic ventricular tachycardia in Bedouin families from Israel. Am J Hum Genet 2001;69(6):1378-84
   PubMed Web of Science ®Google Scholar
• Priori SG, Corr PB. Mechanisms underlying early and delayed afterdepolarizations induced by catecholamines. Am J Physiol 1990;258(6 Pt 2):H1796-805
   Google Scholar
• Liu N, Colombi B, Memmi M, et al. Arrhythmogenesis in catecholaminergic polymorphic ventricular tachycardia: insights from a RyR2 R4496C knock-in mouse model. Circ Res 2006;99(3):292-8
   PubMed Web of Science ®Google Scholar
• Postma AV, Denjoy I, Hoorntje TM, et al. Absence of calsequestrin 2 causes severe forms of catecholaminergic polymorphic ventricular tachycardia. Circ Res 2002;91(8):e21-6
   Google Scholar
• Leenhardt A, Lucet V, Denjoy I, et al. Catecholaminergic polymorphic ventricular tachycardia in children. A 7-year follow-up of 21 patients. Circulation 1995;91(5):1512-19
   PubMed Web of Science ®Google Scholar
• Postma AV, Denjoy I, Kamblock J, et al. Catecholaminergic polymorphic ventricular tachycardia: RYR2 mutations, bradycardia, and follow up of the patients. J Med Genet 2005;42(11):863-70
   PubMedGoogle Scholar
• Aizawa Y, Komura S, Okada S, et al. Distinct U wave changes in patients with catecholaminergic polymorphic ventricular tachycardia (CPVT). Intl Heart J 2006;47(3):381-9
   PubMedGoogle Scholar
• Marjamaa A, Hiippala A, Arrhenius B, et al. Intravenous epinephrine infusion test in diagnosis of catecholaminergic polymorphic ventricular tachycardia. J Cardiovasc Electrophysiol 2012;23(2):194-9
   PubMedGoogle Scholar
• van der Werf C, Nederend I, Hofman N, et al. Familial evaluation in catecholaminergic polymorphic ventricular tachycardia: disease penetrance and expression in cardiac ryanodine receptor mutation-carrying relatives. Circ Arrhythm Electrophysiol 2012;5(4):748-56
   PubMedGoogle Scholar
• Hayashi M, Denjoy I, Extramiana F, et al. Incidence and risk factors of arrhythmic events in catecholaminergic polymorphic ventricular tachycardia. Circulation 2009;119(18):2426-34
   PubMed Web of Science ®Google Scholar
• Odero A, Bozzani A, De Ferrari GM, Schwartz PJ. Left cardiac sympathetic denervation for the prevention of life-threatening arrhythmias: the surgical supraclavicular approach to cervicothoracic sympathectomy. Heart Rhythm 2010;7(8):1161-5
   PubMedGoogle Scholar
• Kannankeril P. A prospective randomized crossover trial of oral flecainide for Catecholaminergic polymorphic ventricular tachycardia. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2010. NLM Identifier: NCT01117454 Available from: http://clinicaltrials.gov/showNCT01117454 [Last accessed 1 June 2013]
   Google Scholar
• Denegri M, Avelino-Cruz JE, Boncompagni S, et al. Viral gene transfer rescues arrhythmogenic phenotype and ultrastructural abnormalities in adult calsequestrin-null mice with inherited arrhythmias. Circ Res 2012;110(5):663-8
   PubMed Web of Science ®Google Scholar
• Priori SG, Pandit SV, Rivolta I, Berenfeld O. A novel form of short QT syndrome (SQT3) is caused by a mutation in the KCNJ2 gene. Circ Res 2005;96:800-7
   PubMed Web of Science ®Google Scholar